Close
CDMO Safety Testing 2026
Novotech
Production & Manufacturing

Amgen to invest $200m in new Singapore manufacturing facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Drug Research

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.
Drug Research

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....
Business & Industry

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...
- Advertisement -

Amgen is planning to invest $200m to construct a manufacturing facility in the Tuas Biomedical Park area of Singapore.

Company intends to begin the construction of the new facility shortly to expand the monoclonal antibody manufacturing capacity.

Amgen operations executive vice president Madhu Balachandran said the planning for the new Singapore facility is a part of the strategic global expansion.

“Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” Balachandran added.

New facility, which is expected to employ fresh recruits along with experienced staff, will manufacture both clinical and commercial products.

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.
Download the Media Pack to activate your presence across the global pharma and life sciences ecosystem.

Latest stories

Previous article
Impax, Perrigo to jointly develop topical generic drug
Next article
PCT to provide development, manufacturing services to Adaptimmune

Related stories

Drug Research

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.
Drug Research

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....
Business & Industry

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...
Business & Industry

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Decentralized Clinical Trials

Decentralized Clinical Trials Market Advances Worldwide

bioprocess analytics biologics manufacturing

Bioprocess Analytics Improving Biologics Manufacturing